Influences, Barriers, and Facilitators to COVID-19 Vaccination: Cross-sectional Survey on Vaccine Hesitancy in 2 Rural States

Elaine Nguyen¹, MPH, PharmD; Melanie Wright¹, PhD; John Holmes², MPH, PharmD; Kevin Cleveland¹, PharmD; Catherine Oliphant¹, PharmD; Mary Nies³, PhD; Renee Robinson⁴, MPH, MSPharm, PharmD

¹Department of Pharmacy Practice and Administration, College of Pharmacy, Idaho State University, Meridian, ID, United States
²Department of Pharmacy Practice and Administration, College of Pharmacy, Idaho State University, Pocatello, ID, United States
³School of Nursing, College of Health, Pocatello, ID, United States
⁴Department of Pharmacy Practice and Administration, College of Pharmacy, University of Alaska/Idaho State University, Anchorage, AK, United States

Corresponding Author:
Renee Robinson, MPH, MSPharm, PharmD
Department of Pharmacy Practice and Administration
College of Pharmacy
University of Alaska/Idaho State University
2533 Providence Drive PSB111
Anchorage, AK, 99508
United States
Phone: 1 907 786 6233
Email: robiren2@isu.edu

Abstract

Background: Vaccination remains one of the most effective ways to limit the spread of infectious diseases such as that caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. Unfortunately, vaccination hesitancy continues to be a threat to national and global health. Further research is necessary to determine the modifiable and nonmodifiable factors contributing to COVID-19 vaccine hesitancy in under-resourced, underserved, and at-risk rural and urban communities.

Objective: This study aimed to identify, understand, and address modifiable barriers and factors contributing to COVID-19 vaccine hesitancy among vaccine-eligible individuals with access to the vaccine in Alaska and Idaho.

Methods: An electronic survey based on the World Health Organization (WHO) Strategic Advisory Group on Experts (SAGE) on Immunization survey tool and investigators’ previous work was created and distributed in June 2021 and July 2021. To be eligible to participate in the survey, individuals had to be ≥18 years of age and reside in Alaska or Idaho. Responses were grouped into 4 mutually exclusive cohorts for data analysis and reporting based on intentions to be vaccinated. Respondent characteristics and vaccine influences between cohorts were compared using Chi-square tests and ANOVA. Descriptive statistics were also used.

Results: There were data from 736 usable surveys with 40 respondents who did not intend to be vaccinated, 27 unsure of their intentions, 8 who intended to be fully vaccinated with no doses received, and 661 fully vaccinated or who intended to be vaccinated with 1 dose received. There were significant differences in characteristics and influences between those who were COVID-19 vaccine-hesitant and those who had been vaccinated. Concerns related to possible side effects, enough information on long-term side effects, and enough information that is specific to the respondent’s health conditions were seen in those who did not intend to be fully vaccinated and unsure about vaccination. In all cohorts except those who did not intend to be fully vaccinated, more information about how well the vaccine works was a likely facilitator to vaccination.

Conclusions: These survey results from 2 rural states indicate that recognition of individual characteristics may influence vaccine choices. However, these individual characteristics represent only a starting point to delivering tailored messages that should come from trusted sources to address vaccination barriers.

(JMIR Form Res 2022;6(12):e39109) doi: 10.2196/39109

https://formative.jmir.org/2022/12/e39109
KEYWORDS
COVID-19; COVID-19 vaccines; vaccine hesitancy; cross-sectional studies; rural populations

Introduction

Immunization is the greatest public health achievement of all time, saving over 3 million lives worldwide each year [1,2]. State and national immunization programs have been so successful that many Americans view the risks of vaccine-preventable diseases such as measles, pertussis, and polio as minimal [1]. Vaccination remains one of the most effective ways to limit the spread of infectious diseases such as that caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19 [3]. However, waning public confidence in vaccines, especially the COVID-19 vaccine, remains a cause for concern [4-9]. In addition, believed threshold requirements for vaccination to achieve herd immunity have shifted and increased with new variants [10,11]. As of August 2022, ~67% of the total population had been fully vaccinated (ie, primary series completed) [12], but there continues to be a need for both primary series completion and booster doses [13].

Vaccine hesitancy, one of the top 10 threats to global health, is the delay or refusal to receive a vaccine, despite access, availability, and perceived effectiveness of the vaccine [5]. Preliminary research suggests that health decisions, such as to receive or not receive a vaccine, are highly influenced by social and cultural factors (eg, political ideology, past experiences with health services, family histories, the moral dilemma between individual autonomy and the greater public health) [6,13,14]. In addition, several other complex factors may be contributing to the increased hesitancy that has been noted with the COVID-19 vaccine [5,8,15].

Given the importance of this topic, researchers have been seeking to better understand acceptability of COVID-19 vaccination and drivers of hesitancy. Global surveys conducted in different countries have shown concerns for vaccine safety and effectiveness [16-21]. At the beginning of the pandemic in May 2020, an online survey of Americans found that 69% of respondents were willing to receive a COVID-19 vaccine [16]. There were statistically significant differences in those willing and not willing to get vaccinated based on how well the vaccine works and the number of people infected with COVID-19. Since this initial survey was conducted, the COVID-19 vaccination landscape has continued to shift in the United States and globally.

With complex factors impacting vaccination decisions, further research is necessary to determine the modifiable and nonmodifiable factors contributing to COVID-19 vaccine hesitancy in under-resourced, underserved, and at-risk rural and urban communities. The goal of this project was to identify, understand, and address modifiable barriers and factors contributing to COVID-19 vaccine hesitancy among vaccine-eligible individuals with access to the vaccine in Alaska and Idaho. The primary goal of this paper was to present the results from a vaccine hesitancy survey.

Methods

Survey Details

The survey was based on the World Health Organization (WHO) Strategic Advisory Group on Experts (SAGE) on Immunization survey tool and investigators’ previous qualitative work with residents of Alaska and Idaho who remain hesitant to receive the COVID-19 vaccine [1,22,23]. Some survey questions from the WHO SAGE were previously validated, and some were from field experts. The draft survey underwent several revisions and was reviewed multiple times by project investigators (n=7) and the project advisory board. The advisory board (n=11) was composed of community members, health care providers, and public health organization representatives. Although the final survey was extensively reviewed, it did not undergo any formal validation studies.

The survey (Multimedia Appendix 1) was estimated to take 10 minutes and included 31 questions divided into 4 parts: introduction, barriers and facilitators, influences, and demographics. All questions, except those in the introduction (eligibility screening and vaccination status), were optional. To be eligible to participate in the survey, individuals had to be ≥18 years of age and reside in Alaska or Idaho. The focus on this population was to capture adult perspectives from primarily rural states.

The survey was created and made available via Qualtrics online survey software. It was distributed through project investigators and advisory board member contacts. It was also promoted in Facebook advertisements. A broad defined audience was used for the Facebook advertisements, with advertisements targeting only location (Alaska or Idaho) and age (≥18 years). The survey was available for approximately 1 month, with responses collected from June 11, 2021, through July 16, 2021.

Data Analysis

Given the broad survey distribution, responses were reviewed for validity, and responses deemed potentially invalid were removed from analysis. Responses were removed if at least one of the following criteria were met: The survey was not finished, completed multiple times from the same IP address with no unique free-text responses, or not completed in Alaska and Idaho (as determined by GPS coordinates). IP address and GPS data are automatically collected in the Qualtrics survey platform. Eligible and valid responses were included in the data analysis. Respondents were grouped into 4 mutually exclusive cohorts: (1) did not intend to be fully vaccinated, (2) were unsure of their vaccination intentions, (3) intended to be fully vaccinated but had not yet received their first dose, and (4) were fully vaccinated or intended to be fully vaccinated and had received at least 1 dose. When comparing respondent characteristics and vaccine influences between cohorts, Chi-square tests (for nominal data) and ANOVA (for continuous data) were used. P values <.05 were considered statistically significant when comparing respondent characteristics. When comparing vaccine
influences, a Bonferroni correction with a \( P \) value <.007 was considered statistically significant. Descriptive statistics (counts and percentages) were used to describe barriers, facilitators, and trust in sources for vaccine information. Cronbach alpha was also used to measure reliability for barriers, facilitators, and trust in sources for vaccine information.

**Ethical Considerations**

This work underwent an expedited review and was approved by the Idaho State University Institutional Review Board (IRB-FY2021-256). Respondents indicated their consent to participate after reading survey background information (eg, purpose, estimated completion time) and by continuing to the next survey page.

After determining if a response was valid and categorizing the response into a mutually exclusive cohort, any individual response data not associated with survey responses were removed for analysis to protect respondent privacy. To incentivize participation, a raffle to be entered to win one of 20 US $100 Amazon electronic gift cards was offered. To maintain respondent privacy, raffle information was collected in a separate form to keep survey responses anonymous.

**Results**

After removal of invalid responses, there were data from 736 usable surveys: 40 respondents did not intend to be vaccinated, and 27 were unsure of their intentions. Although 8 respondents had not yet received any COVID-19 vaccine, they had intended to be fully vaccinated. Lastly, 661 respondents were fully vaccinated (n=654) or intended to be fully vaccinated with 1 dose received (n=7). Characteristics of survey respondents are presented in Table 1. There were statistically significant differences across cohorts among all characteristics evaluated (see \( P \) values in Table 1).

The intended to be vaccinated cohort with no doses received had the lowest mean age (33.3 years), but this sample size was small. Those who were fully vaccinated or intended to be fully vaccinated with at least 1 dose received had the oldest mean age (59.1 years). Of those who did not intend to be vaccinated, the lowest age of a respondent was 35 years, whereas the other cohorts had younger respondents. The distribution of respondents’ ages by cohorts is available in Multimedia Appendix 2.

Nearly 90% (7/8, 88%) of respondents in the intended to be fully vaccinated but had not yet received their first dose cohort were men versus only 18.0% (119/661) in the fully vaccinated/intended to be fully vaccinated with 1 dose received cohort. One-half (20/40, 50%) of those who did not intend to be fully vaccinated identified as Christian, whereas only 34.5% (231/669) of those who intended to be fully vaccinated or were already fully vaccinated were Christian. Conversely, a reverse pattern was seen across these cohorts with those who were agnostic, atheist, or believed in nothing in particular. In those who did not intend to be vaccinated, the largest political preference was Republican (17/40, 43%). In those fully vaccinated/intended to be fully vaccinated with 1 dose received, the largest political preference was Democrat (314/661, 47.5%). Across cohorts, there were statistical differences in race and ethnicity, but overall, the groups were predominantly White and not Hispanic nor Latino. The majority of respondents had health insurance (702/736, 95.4%), with only 22 (22/736, 3.0%) reporting no insurance; 12 (12/736, 1.6%) were unsure or chose not to share their health insurance status.

When assessing vaccine influences, there continued to be differences across cohorts (Table 2). Only 25% (10/40) of those who did not intend to be vaccinated had a medium-high perceived risk of getting COVID-19 versus 43.0% (284/661) of those fully vaccinated/intended to be fully vaccinated. Interestingly, the percentage of those who had prior COVID-19 and had been really sick was twice as high in those with no plans of vaccination versus those fully vaccinated/intended to be fully vaccinated (5/40, 13% vs 39/661, 5.9%). Of the respondents, 90.2% (664/736) knew somebody who had COVID-19, and nearly one-third (239/736, 32.5%) knew somebody who had died from the disease. The proportion of those knowing somebody who died from COVID-19 was lower in those who did not intend to be vaccinated than in the other cohorts. Significant differences were seen in beliefs that vaccines work to prevent diseases and, related to this belief, the typical receipt of the influenza vaccine.

Data represented in Tables 3-5 represent descriptive statistics only. From these data, concerns related to possible side effects, enough information on long-term side effects, and enough information that is specific to respondents’ health conditions were seen in those who did not intend to be fully vaccinated and unsure about vaccination (Table 3). Practical factors for vaccination (ie, scheduling, time away from daily responsibilities for vaccination and side effects, child supervision) were not seen as barriers. The Cronbach alpha for barriers was 0.8184. In all cohorts except those who did not intend to be fully vaccinated, more information about how well the vaccine works is a likely facilitator to vaccination (Table 4). Factors such as payment to get the vaccine or requirements for work or travel were not likely facilitators or motivators to vaccination across all cohorts. The Cronbach alpha for facilitators was 0.7279.

In those not planning to receive the vaccine, there was low trust from most sources of information (Table 5). In those unsure, a primary care provider or doctor and pharmacist were the most trusted sources of information. This trend was also seen in those who intended to be fully vaccinated or those already fully vaccinated. The Cronbach alpha for trust in sources of vaccine information was 0.8239.
Table 1. Respondent characteristics.

| Characteristic                        | Did NOT intend to be fully vaccinated (n=40) | Unsure of full vaccination intentions (n=27) | Intended to be fully vaccinated with no doses received (n=8) | Fully vaccinated OR intended to be with 1 dose received (n=661) | All (N=736) | P value |
|---------------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-------------|---------|
| Age (years), mean (SD)                | 56.6 (11.0)                                 | 54.9 (15.6)                                 | 33.3 (12.0)                                               | 59.1 (14.5)                                               | 58.4 (14.7) | <.001   |
| Age (years), median (range)           | 55.0 (35-92)                                | 55.0 (25-80)                                | 29.5 (23-61)                                              | 63.0 (18-85)                                              | 62.0 (18-92) | N.a.    |

**Gender identity, n (%)**

| Man                                   | 12 (30.0)                                   | 4 (14.8)                                   | 7 (87.5)                                                  | 119 (18.0)                                                | 142 (19.3)  | .001    |
| Woman                                 | 26 (65.0)                                   | 22 (81.5)                                  | 1 (12.5)                                                  | 531 (80.3)                                                | 580 (78.8)  |         |
| Other                                 | 1 (2.5)                                     | 0 (0)                                      | 0 (0)                                                     | 5 (0.8)                                                   | 6 (0.8)     |         |
| Prefer not to say/no response         | 1 (2.5)                                     | 1 (3.7)                                    | 0 (0)                                                     | 6 (1.0)                                                   | 8 (1.1)     |         |

**Race b, n (%)**

| Alaska Native                         | 0 (0)                                       | 1 (3.4)                                    | 1 (12.5)                                                  | 1 (0.2)                                                   | 3 (0.4)     | <.001   |
| American Indian/Native American       | 2 (5.0)                                     | 1 (3.4)                                    | 0 (0)                                                     | 7 (1.1)                                                   | 10 (1.4)    |         |
| Asian                                 | 0 (0)                                       | 0 (0)                                      | 0 (0)                                                     | 9 (1.4)                                                   | 9 (1.2)     |         |
| Black/African American                | 0 (0)                                       | 0 (0)                                      | 2 (25.0)                                                  | 2 (0.3)                                                   | 4 (0.5)     |         |
| Native Hawaiian/Pacific Islander      | 0 (0)                                       | 0 (0)                                      | 0 (0)                                                     | 2 (0.3)                                                   | 2 (0.3)     |         |
| White                                 | 34 (85.0)                                   | 26 (89.7)                                  | 5 (62.5)                                                  | 633 (95.8)                                                | 698 (94.8)  |         |
| Other                                 | 2 (5.0)                                     | 0 (0)                                      | 0 (0)                                                     | 7 (1.1)                                                   | 9 (1.2)     |         |
| Prefer not to say/no response         | 2 (5.0)                                     | 1 (3.4)                                    | 1 (12.5)                                                  | 13 (2.0)                                                  | 17 (2.3)    |         |

**Ethnicity, n (%)**

| Hispanic/Latino                       | 1 (2.5)                                     | 3 (11.1)                                   | 1 (12.5)                                                  | 12 (1.8)                                                  | 17 (2.3)    | .009    |
| Not Hispanic/Latino                   | 29 (72.5)                                   | 19 (70.4)                                  | 6 (75.0)                                                  | 547 (82.8)                                                | 601 (81.7)  |         |
| Other                                 | 1 (2.5)                                     | 1 (3.7)                                    | 0 (0)                                                     | 43 (6.5)                                                  | 45 (5.1)    |         |
| Prefer not to say/no response         | 9 (22.5)                                    | 4 (14.8)                                   | 1 (12.5)                                                  | 59 (8.9)                                                  | 73 (9.9)    |         |

**State, n (%)**

| Alaska                                | 0 (0)                                       | 5 (18.5)                                   | 5 (62.5)                                                  | 15 (2.3)                                                  | 25 (3.4)    | <.001   |
| Idaho                                 | 40 (100)                                    | 22 (81.5)                                  | 3 (37.5)                                                  | 646 (97.7)                                                | 711 (96.6)  |         |

**Religion b, n (%)**

| Agnostic/atheist/nothing in particular| 3 (7.5)                                     | 5 (18.5)                                   | 2 (25.0)                                                  | 227 (34.3)                                                | 237 (32.2)  | <.001   |
| Christian                             | 20 (50.0)                                   | 11 (40.7)                                  | 5 (62.5)                                                  | 226 (34.2)                                                | 262 (35.6)  |         |
| Jewish                                | 1 (2.5)                                     | 0 (0)                                      | 0 (0)                                                     | 6 (0.9)                                                   | 7 (1.0)     |         |
| Mormon                                | 5 (12.5)                                    | 6 (22.2)                                   | 0 (0)                                                     | 109 (16.5)                                                | 120 (16.3)  |         |
| Muslim                                | 1 (2.5)                                     | 0 (0)                                      | 1 (12.5)                                                  | 0 (0)                                                     | 2 (0.3)     |         |
| Roman Catholic                        | 3 (7.5)                                     | 3 (11.1)                                   | 0 (0)                                                     | 56 (8.5)                                                  | 62 (8.4)    |         |
| Other                                 | 2 (5.0)                                     | 2 (7.4)                                    | 0 (0)                                                     | 37 (5.6)                                                  | 41 (5.6)    |         |
| Prefer not to say/no response         | 6 (15.0)                                    | 3 (11.1)                                   | 0 (0)                                                     | 38 (5.7)                                                  | 47 (6.4)    |         |

**Political preference b, n (%)**
| Characteristic                                      | Did NOT intend to be fully vaccinated (n=40) | Unsure of full vaccination intentions (n=27) | Intended to be fully vaccinated with no doses received (n=8) | Fully vaccinated OR intended to be with 1 dose received (n=661) | All (N=736) | P value |
|----------------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|-------------|---------|
| Democrat                                           | 2 (5.0)                                    | 5 (18.5)                                   | 1 (12.5)                                                    | 314 (47.5)                                                  | 322 (42.8)  | <.001   |
| Republican                                         | 17 (42.5)                                  | 7 (25.9)                                   | 4 (50.0)                                                    | 110 (16.6)                                                  | 138 (18.8)  |         |
| Independent                                        | 9 (22.5)                                   | 7 (25.9)                                   | 3 (37.5)                                                    | 193 (29.2)                                                  | 212 (28.8)  |         |
| Other                                              | 2 (5.0)                                    | 3 (11.1)                                   | 0 (0)                                                       | 51 (7.7)                                                    | 56 (7.6)    |         |
| Prefer not to say/no response                      | 10 (25.0)                                  | 7 (25.9)                                   | 0 (0)                                                       | 55 (8.3)                                                    | 72 (9.8)    |         |
| **Highest grade finished/degree received, n (%)**  |                                            |                                            |                                                             |                                                             |             |         |
| High school graduate/GED or less                   | 2 (5.0)                                    | 1 (3.7)                                    | 1 (12.5)                                                    | 26 (3.9)                                                    | 30 (4.1)    | .003    |
| Some college, no degree/associate degree           | 16 (40.0)                                  | 12 (44.4)                                  | 2 (25.0)                                                    | 150 (22.7)                                                  | 180 (24.5)  |         |
| Bachelor degree                                    | 11 (27.5)                                  | 4 (14.8)                                   | 2 (25.0)                                                    | 226 (34.2)                                                  | 243 (33.0)  |         |
| Postbachelor degree                                | 9 (22.5)                                   | 6 (22.2)                                   | 3 (37.5)                                                    | 242 (36.6)                                                  | 260 (35.3)  |         |
| Other                                              | 2 (5.0)                                    | 4 (14.8)                                   | 0 (0)                                                       | 14 (2.1)                                                    | 20 (2.7)    |         |
| Prefer not to say/no response                      | 0 (0)                                      | 0 (0)                                      | 0 (0)                                                       | 3 (0.5)                                                     | 3 (0.4)     |         |
| **Employment status**                              |                                            |                                            |                                                             |                                                             |             | <.001   |
| Employed by government (local, state, and federal) | 4 (10.0)                                   | 3 (11.1)                                   | 3 (37.5)                                                    | 106 (16.0)                                                  | 116 (15.8)  | <.001   |
| Employed by a private company (for-profit and nonprof- | 12 (30.0)                                  | 6 (25.9)                                   | 4 (50.0)                                                    | 130 (19.7)                                                  | 152 (20.7)  |         |
| Other                                              | 18 (45.0)                                  | 17 (63.0)                                  | 1 (12.5)                                                    | 441 (66.7)                                                  | 477 (64.8)  |         |
| Prefer not to say/no response                      | 8 (20.0)                                   | 2 (7.4)                                    | 0 (0)                                                       | 11 (1.7)                                                    | 21 (2.9)    |         |

*aNot calculated.

*bRespondents could select all that apply; the sum of the percentages may be >100.
Table 2. Factors influencing the decision to be vaccinated.

| Influence                                      | Did NOT intend to be fully vaccinated (n=40), n (%) | Unsure of full vaccination intentions (n=27), n (%) | Intended to be fully vaccinated with no doses received (n=8), n (%) | Fully vaccinated OR intended to be with 1 dose received (n=661), n (%) | All (N=736), n (%) | P value |
|------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------|---------|
| **Perceived risk of getting COVID-19**          |                                                  |                                                  |                                                 |                                                 |                   |         |
| None                                           | 9 (22.5)                                         | 0 (0)                                           | 1 (12.5)                                        | 37 (5.6)                                        | 47 (6.4)          | .004    |
| Low                                            | 21 (52.5)                                        | 15 (55.6)                                       | 5 (62.5)                                        | 340 (51.4)                                      | 381 (51.8)        |         |
| Medium                                         | 9 (22.5)                                         | 9 (33.3)                                        | 1 (12.5)                                        | 198 (30.0)                                      | 217 (29.5)        |         |
| High                                           | 1 (2.5)                                          | 3 (11.1)                                        | 1 (12.5)                                        | 86 (13.0)                                       | 91 (12.4)         |         |
| **Perceived risk of getting really sick from COVID-19** |                                                  |                                                  |                                                 |                                                 |                   |         |
| None                                           | 11 (27.5)                                        | 4 (14.8)                                        | 0 (0)                                           | 53 (8.0)                                        | 68 (9.2)          | __a     |
| Low                                            | 20 (50.0)                                        | 10 (37.0)                                       | 4 (50.0)                                        | 283 (42.8)                                      | 317 (43.1)        |         |
| Medium                                         | 7 (17.5)                                         | 6 (22.2)                                        | 1 (12.5)                                        | 199 (30.1)                                      | 213 (28.9)        |         |
| High                                           | 2 (5.0)                                          | 7 (25.9)                                        | 3 (37.5)                                        | 125 (18.9)                                      | 137 (18.6)        |         |
| No response                                    | 0 (0)                                            | 0 (0)                                           | 0 (0)                                           | 1 (0.2)                                         | 1 (0.1)           |         |
| **Prior COVID-19**                             |                                                  |                                                  |                                                 |                                                 |                   |         |
| No                                             | 20 (50.0)                                        | 10 (37.0)                                       | 6 (75.0)                                        | 498 (75.3)                                      | 534 (72.6)        | <.001   |
| Unsure                                         | 10 (25.0)                                        | 9 (33.3)                                        | 0 (0)                                           | 76 (11.5)                                       | 95 (12.9)         |         |
| Yes, minor/no symptoms                         | 4 (10.0)                                         | 5 (18.5)                                        | 2 (25.0)                                        | 46 (7.0)                                        | 57 (7.7)          |         |
| Yes, really sick                               | 5 (12.5)                                         | 3 (11.1)                                        | 0 (0)                                           | 39 (5.9)                                        | 47 (6.4)          |         |
| No response                                    | 1 (2.5)                                          | 0 (0)                                           | 0 (0)                                           | 2 (0.3)                                         | 3 (0.4)           |         |
| **Known somebody who had COVID-19, worst outcome** |                                                  |                                                  |                                                 |                                                 |                   |         |
| No                                             | 5 (12.5)                                         | 1 (3.7)                                         | 3 (37.5)                                        | 41 (6.2)                                        | 50 (6.8)          | <.001   |
| Unsure                                         | 0 (0)                                            | 2 (7.4)                                         | 0 (0)                                           | 18 (2.7)                                        | 20 (2.7)          |         |
| Yes, only minor/no symptoms                    | 18 (45.0)                                        | 7 (25.9)                                        | 3 (37.5)                                        | 121 (18.3)                                      | 149 (20.2)        |         |
| Yes, really sick                               | 12 (30.0)                                        | 7 (25.9)                                        | 0 (0.0)                                         | 257 (38.9)                                      | 276 (37.5)        |         |
| Yes, died                                      | 4 (10.0)                                         | 10 (37.0)                                       | 2 (25.0)                                        | 223 (33.7)                                      | 239 (32.5)        |         |
| No response                                    | 1 (2.5)                                          | 0 (0)                                           | 0 (0)                                           | 1 (0.2)                                         | 2 (0.3)           |         |
| **Belief that vaccines work to prevent diseases** |                                                  |                                                  |                                                 |                                                 |                   |         |
| Not at all                                     | 4 (10.0)                                         | 0 (0)                                           | 0 (0)                                           | 0 (0)                                           | 4 (0.5)           | <.001   |
| A little                                       | 8 (20.0)                                         | 6 (22.2)                                        | 0 (0)                                           | 5 (0.8)                                         | 19 (2.6)          |         |
| A moderate amount                              | 14 (35.0)                                        | 5 (18.5)                                        | 4 (50.0)                                        | 47 (7.1)                                        | 70 (9.5)          |         |
| A lot                                          | 13 (32.5)                                        | 16 (59.3)                                       | 4 (50.0)                                        | 608 (92.0)                                      | 641 (87.1)        |         |
| No response                                    | 1 (2.5)                                          | 0 (0)                                           | 0 (0)                                           | 1 (0.2)                                         | 2 (0.3)           |         |
| **Typical receipt of flu vaccine**              |                                                  |                                                  |                                                 |                                                 |                   |         |
| No                                             | 31 (77.5)                                        | 13 (48.1)                                       | 1 (12.5)                                        | 92 (13.9)                                       | 137 (18.6)        | <.001   |
| Unsure                                         | 0 (0)                                            | 1 (3.7)                                         | 2 (25.0)                                        | 7 (1.1)                                         | 10 (1.4)          |         |
| Yes                                            | 8 (20.0)                                         | 12 (44.4)                                       | 5 (62.5)                                        | 557 (84.3)                                      | 582 (79.1)        |         |
| Prefer not to say/no response                  | 1 (2.5)                                          | 1 (3.7)                                         | 0 (0)                                           | 5 (0.8)                                         | 7 (1.0)           |         |
| **Worrisome allergies with COVID-19 vaccine**   |                                                  |                                                  |                                                 |                                                 |                   |         |
| Influence | Did NOT intend to be fully vaccinated (n=40), n (%) | Unsure of full vaccination intentions (n=27), n (%) | Intended to be fully vaccinated with no doses received (n=8), n (%) | Fully vaccinated OR intended to be with 1 dose received (n=661), n (%) | All (N=736), n (%) | P value |
|-----------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------|---------|
| No        | 26 (65.0)                                     | 12 (44.4)                                     | 3 (37.5)                                        | 588 (89.0)                                     | 629 (85.5)      | <.001   |
| Unsure    | 6 (15.0)                                      | 3 (11.1)                                      | 2 (25.0)                                        | 27 (4.1)                                       | 38 (5.2)        |         |
| Yes       | 5 (12.5)                                      | 12 (44.4)                                     | 3 (37.5)                                        | 42 (6.4)                                       | 62 (8.4)        |         |
| Prefer not to say | 3 (7.5)                                      | 0 (0)                                         | 0 (0)                                           | 4 (0.6)                                        | 7 (1.0)         |         |

Table 3. Barriers to vaccination.

| Barrier        | Did NOT intend to be fully vaccinated (n=40), n (%) | Unsure of full vaccination intentions (n=27), n (%) | Intended to be fully vaccinated with no doses received (n=8), n (%) | Fully vaccinated OR intended to be with 1 dose received (n=661), n (%) | Not at all/little | Moderately/a lot | Not at all/little | Moderately/a lot | Not at all/little | Moderately/a lot | Not at all/little | Moderately/a lot |
|----------------|---------------------------------------------------|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Enough trusted information about the vaccine | 18 (45.0)                                       | 22 (55.0)                                    | 8 (29.6)                                        | 18 (66.7)                                       | 1 (12.5)        | 7 (87.5)        | 573 (86.7)      | 87 (13.2)       |                  |                 |                 |                 |
| Enough information about the vaccine in respondent language | 30 (75.0)                                       | 10 (25.0)                                    | 19 (70.4)                                       | 7 (25.9)                                        | 3 (37.5)        | 5 (62.5)        | 611 (92.4)      | 43 (6.5)        |                  |                 |                 |                 |
| Enough information on short-term vaccine side effects | 22 (55.0)                                       | 18 (45.0)                                    | 8 (29.6)                                        | 18 (66.7)                                       | 3 (37.5)        | 5 (62.5)        | 560 (84.7)      | 95 (14.4)       |                  |                 |                 |                 |
| Enough information on long-term vaccine side effects | 11 (27.5)                                       | 29 (72.5)                                    | 4 (14.8)                                        | 22 (81.5)                                       | 2 (25.0)        | 6 (75.0)        | 519 (78.5)      | 134 (20.3)      |                  |                 |                 |                 |
| Enough information about the vaccine that is specific to respondent’s health conditions | 13 (32.5)                                       | 27 (67.5)                                    | 6 (22.2)                                        | 21 (77.8)                                       | 2 (25.0)        | 6 (75.0)        | 552 (83.5)      | 96 (14.5)       |                  |                 |                 |                 |
| Process of scheduling a vaccine appointment | 40 (100)                                        | 0 (0)                                        | 25 (92.6)                                       | 1 (3.7)                                         | 5 (62.5)        | 3 (37.5)        | 518 (78.4)      | 142 (21.5)      |                  |                 |                 |                 |
| Possible side effects from the vaccine | 8 (20.0)                                        | 32 (80.0)                                    | 5 (18.5)                                        | 22 (81.5)                                       | 0 (0)           | 8 (100)         | 596 (90.2)      | 61 (9.2)        |                  |                 |                 |                 |
| Time it takes to get the vaccine | 39 (97.5)                                       | 1 (2.5)                                      | 23 (85.2)                                       | 3 (11.1)                                        | 3 (37.5)        | 5 (62.5)        | 603 (91.2)      | 52 (7.9)        |                  |                 |                 |                 |
| Time off needed from daily responsibilities if side effects were experienced | 26 (65.0)                                       | 14 (35.0)                                    | 17 (63.0)                                       | 9 (33.3)                                        | 3 (37.5)        | 5 (62.5)        | 587 (88.8)      | 68 (10.3)       |                  |                 |                 |                 |
| Child supervision | 30 (75.0)                                       | 1 (2.5)                                      | 21 (77.8)                                       | 2 (7.4)                                         | 7 (87.5)        | 1 (12.5)        | 434 (65.7)      | 14 (2.1)        |                  |                 |                 |                 |

aNot performed due to low cell counts.
bNot applicable for all respondents.

aThere are no responses that are not shown in the table.

bNot applicable for all respondents.
Table 4. Facilitators to vaccination.

| Facilitator                                      | Fully vaccinated OR intended to be with 1 dose received (n=661), n (%) | Intended to be fully vaccinated with no doses received (n=8), n (%) | Unsure of full vaccination intentions (n=27), n (%) | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot |
|--------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Somebody trusted tells to get the vaccine         | 227 (34.3)                                                          | 427 (64.6)                                                      | 7 (87.5)                                          | 427 (64.6)       | 227 (34.3)       | 12 (15.2)                                               | 7 (87.5)                                          | 427 (64.6)       | 227 (34.3)       | 12 (15.2)                                               | 7 (87.5)                                          |
| Interaction with other people who are at high risk of getting really sick from COVID-19 | 36 (90.0)                                                          | 36 (90.0)                                                      | 4 (10.0)                                          | 36 (90.0)       | 36 (90.0)       | 4 (10.0)                                               | 36 (90.0)                                          | 36 (90.0)       | 36 (90.0)       | 4 (10.0)                                               | 36 (90.0)                                          |
| People around the respondent get the vaccine     | 40 (100)                                                           | 23 (55.6)                                                      | 12 (44.4)                                         | 23 (55.6)       | 40 (100)       | 23 (55.6)                                               | 12 (44.4)                                         | 23 (55.6)       | 40 (100)       | 23 (55.6)                                               | 12 (44.4)                                         |
| More information about how well the vaccine works | 35 (87.5)                                                          | 13 (48.1)                                                      | 14 (51.9)                                         | 13 (48.1)       | 35 (87.5)       | 13 (48.1)                                               | 14 (51.9)                                         | 13 (48.1)       | 35 (87.5)       | 13 (48.1)                                               | 14 (51.9)                                         |
| Getting the vaccine at primary care provider’s office | 37 (92.5)                                                          | 18 (66.7)                                                      | 9 (33.3)                                          | 18 (66.7)       | 37 (92.5)       | 18 (66.7)                                               | 9 (33.3)                                          | 18 (66.7)       | 37 (92.5)       | 18 (66.7)                                               | 9 (33.3)                                          |
| Getting the vaccine close to respondent           | 37 (92.5)                                                          | 19 (70.4)                                                      | 8 (29.6)                                          | 19 (70.4)       | 37 (92.5)       | 19 (70.4)                                               | 8 (29.6)                                          | 19 (70.4)       | 37 (92.5)       | 19 (70.4)                                               | 8 (29.6)                                          |
| Paid to get the vaccine                          | 38 (95.0)                                                          | 24 (88.9)                                                      | 3 (11.1)                                          | 24 (88.9)       | 38 (95.0)       | 24 (88.9)                                               | 3 (11.1)                                          | 24 (88.9)       | 38 (95.0)       | 24 (88.9)                                               | 3 (11.1)                                          |
| Required for work                                | 37 (92.5)                                                          | 18 (66.7)                                                      | 9 (33.3)                                          | 18 (66.7)       | 37 (92.5)       | 18 (66.7)                                               | 9 (33.3)                                          | 18 (66.7)       | 37 (92.5)       | 18 (66.7)                                               | 9 (33.3)                                          |
| Required for travel                              | 39 (97.5)                                                          | 19 (70.4)                                                      | 7 (29.5)                                          | 19 (70.4)       | 39 (97.5)       | 19 (70.4)                                               | 7 (29.5)                                          | 19 (70.4)       | 39 (97.5)       | 19 (70.4)                                               | 7 (29.5)                                          |
| No longer have to wear a mask                    | 38 (95.0)                                                          | 19 (70.4)                                                      | 7 (25.9)                                          | 19 (70.4)       | 38 (95.0)       | 19 (70.4)                                               | 7 (25.9)                                          | 19 (70.4)       | 38 (95.0)       | 19 (70.4)                                               | 7 (25.9)                                          |

aThere are no responses that are not shown in the table.

Table 5. Trust in sources for vaccine information

| Source               | Fully vaccinated OR intended to be with 1 dose received (n=661), n (%) | Intended to be fully vaccinated with no doses received (n=8), n (%) | Unsure of full vaccination intentions (n=27), n (%) | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot | Not at all little | Moderately/a lot |
|----------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Family               | 31 (77.5)                                                          | 21 (77.8)                                                      | 6 (22.2)                                          | 21 (77.8)       | 31 (77.5)       | 6 (22.2)                                               | 21 (77.8)                                         | 31 (77.5)       | 6 (22.2)                                               | 21 (77.8)                                         |
| Friends              | 32 (80.0)                                                          | 22 (81.5)                                                      | 4 (18.5)                                          | 22 (81.5)       | 32 (80.0)       | 4 (18.5)                                               | 22 (81.5)                                         | 32 (80.0)       | 4 (18.5)                                               | 22 (81.5)                                         |
| Primary care provider/doctor | 33 (82.5)                                                          | 11 (40.7)                                                      | 16 (59.3)                                         | 11 (40.7)       | 33 (82.5)       | 16 (59.3)                                               | 11 (40.7)                                         | 33 (82.5)       | 16 (59.3)                                               | 11 (40.7)                                         |
| Pharmacist           | 33 (82.5)                                                          | 14 (51.9)                                                      | 13 (48.1)                                         | 14 (51.9)       | 33 (82.5)       | 13 (48.1)                                               | 14 (51.9)                                         | 33 (82.5)       | 13 (48.1)                                               | 14 (51.9)                                         |
| Community leaders    | 35 (87.5)                                                          | 22 (81.5)                                                      | 3 (18.5)                                          | 22 (81.5)       | 35 (87.5)       | 3 (18.5)                                               | 22 (81.5)                                         | 35 (87.5)       | 3 (18.5)                                               | 22 (81.5)                                         |
| Local news           | 34 (85.0)                                                          | 24 (88.9)                                                      | 2 (11.1)                                          | 24 (88.9)       | 34 (85.0)       | 2 (11.1)                                               | 24 (88.9)                                         | 34 (85.0)       | 2 (11.1)                                               | 24 (88.9)                                         |
| National news        | 35 (87.5)                                                          | 22 (81.5)                                                      | 3 (18.5)                                          | 22 (81.5)       | 35 (87.5)       | 3 (18.5)                                               | 22 (81.5)                                         | 35 (87.5)       | 3 (18.5)                                               | 22 (81.5)                                         |
| Social media         | 36 (90.0)                                                          | 24 (88.9)                                                      | 2 (11.1)                                          | 24 (88.9)       | 36 (90.0)       | 2 (11.1)                                               | 24 (88.9)                                         | 36 (90.0)       | 2 (11.1)                                               | 24 (88.9)                                         |
| Celebrities          | 34 (85.0)                                                          | 24 (88.9)                                                      | 2 (11.1)                                          | 24 (88.9)       | 34 (85.0)       | 2 (11.1)                                               | 24 (88.9)                                         | 34 (85.0)       | 2 (11.1)                                               | 24 (88.9)                                         |

aThere are no responses that are not shown in the table.

The survey also included open-ended responses related to reasons for vaccination intentions, barriers, and facilitators. Most of these responses corroborated trends seen in the quantitative data. In those who did not intend to be vaccinated, other notable reasons for not getting vaccinated included the lack of Food and Drug Administration (FDA) approval and the politics and related political pressures surrounding vaccination. Many people in this cohort also noted that “nothing” would make them choose to get fully vaccinated. In those who intended to be fully vaccinated or were fully vaccinated, a major reason noted for their choice was to prevent the spread of COVID-19 and protecting themselves and others. Lastly, in those who had been fully vaccinated, some noted no concerns with vaccination, while others noted the new vaccine, speed of development, effectiveness, and allergic reactions as concerns.

https://formative.jmir.org/2022/12/e39109
Discussion

Principal Findings

The project survey results showed a significant difference in characteristics and influences between those who were COVID-19 vaccine-hesitant (refusing or delaying) and those who had been vaccinated. Similar to national surveys [24,25], there were differences across gender and political preferences, with a greater percentage of men and Republicans in the did not intend to be fully vaccinated cohort versus the vaccinated cohort. Likewise, COVID-19 risk perceptions among those not planning vaccination are lower [24]. Such characteristics, as well as others identified in Table 1, are especially relevant given the demographic characteristics of Alaska and Idaho. For example, more Alaskans and Idahoans politically identify as Republican than Democrat or Independent [26,27].

Although the sample size for respondents in the unsure or intended to be vaccinated cohorts were smaller, these individuals may be especially important to target in vaccination efforts. Addressing vaccine safety, transparency, and sources of information may encourage some individuals to get vaccinated. More information about how well the vaccine works was also seen as an important facilitator. Conveying this information to the lay public can be difficult given the technical and scientific details related to vaccine mechanism of action and how vaccine effectiveness data are calculated, reported, and interpreted [28].

The safety of vaccines (particularly long-term side effects) was noted as a barrier in 80% (28/35) of respondents in the unsure and intended to be vaccinated cohorts. Although case reports have revealed legitimate safety concerns with vaccination (eg, myocarditis and pericarditis with messenger RNA vaccines), risks of severe adverse events are still low [29]. Furthermore, risks of severe adverse events are even higher during and after SAR-CoV-2 infection [30]. A frequent message from the Centers for Disease Control and Prevention has been that COVID-19 vaccines are safe and effective; however, this messaging is not tailored and does not address individual-specific concerns [31]. At least 75% (27/35, 77%) of survey respondents unsure of or delaying vaccination (but intended to be vaccinated) indicated that having enough information about the vaccine that is specific to their health conditions was also a barrier. Therefore, communication needs to also be personalized. It may also be worthwhile to explore ways that local influencers can share their personal experiences or even health systems sharing local data on demographics or characteristics of those vaccinated and their outcomes.

Comparison With Prior Work

Although much previous related work has been done on this topic, the results presented here are unique given the focus on 2 rural states with continued lower vaccination rates. The identified barriers can be utilized with other resources to facilitate vaccination. Along with addressing individual-specific concerns related to vaccine safety and side effects, national organizations have also made recommendations on word choices to improve vaccine acceptance [32]. A 2020 survey by the de Beaumont Foundation (n=1400) found that family was an especially important motivator for vaccination [32]. Therefore, when discussing the benefits of vaccination, focusing on family may be more helpful than focusing on the country, community, or friends. Although the de Beaumont Foundation data suggest that some individuals may be motivated to receive vaccination for their family, results from the VACCINE project survey indicated that being told by a trusted source to get the COVID-19 vaccine was not a facilitator in most cohorts. Furthermore, family members were only seen as a trusted source of vaccine information by ~20% (14/67, 21%) of respondents in the did not intend to be vaccinated and unsure of vaccination cohorts. However, 75% (6/8) of respondents in the intending to be vaccinated cohorts stated that family was a trusted source, but these results may be skewed due to the lower sample size.

For those unsure or intended to be vaccinated, health care personnel (primary care provider or doctor and pharmacist) were the most trusted source for vaccine information. Health care providers can leverage their position to provide a strong recommendation for vaccination, which has been shown in the past to increase likelihood of vaccination against influenza [31,33-35]. Professionals play a key role in influencing the decision to receive the influenza vaccine. Information about influenza and its vaccine needs to be combined with improvements in service provision if overall target uptake rates of 70% (65% in those aged 65 years and over) are to be achieved [33,34]. Of concern is vaccine misinformation (and disinformation) especially from health care providers [36,37], which has been discussed in recent news outlets. Misinformation can impact intention to vaccinate [38] and has been identified by the US Surgeon General as an urgent public threat [39].

Limitations

The landscape of the COVID-19 pandemic is rapidly changing, which may impact some of the findings from this cross-sectional work. Since the VACCINE survey was disseminated in mid-June, the proportion of the circulating virus as the Omicron variant increased from 6.3% to 78.4% (as of March 2022), and new variants have arisen. In August 2021, the FDA approved the first COVID-19 vaccine [40]. Since this time period, there have also been increases in vaccination requirements (eg, as seen in President Biden’s COVID-19 Action Plan). Although these national changes have been significant, vaccination rates in Alaska and Idaho are still dismal and below the national average. There continues to be a need to address barriers contributing to vaccine hesitancy in these rural states. Because this work focused specifically on respondents from these 2 states, the broader generalizability to other populations may be limited. Other limitations of this work include a small sample size, especially for those who intended to be fully vaccinated with no doses received, and the use of Facebook advertisements to recruit participants such as this may introduce response bias.

Conclusions

Efforts to counter vaccine misinformation, address hesitancy, and increase confidence continue to be underway to increase COVID-19 vaccination rates [41]. It is important that targeted approaches are taken in diverse communities (eg, rural areas). The project survey results from 2 rural states indicate that recognition of individual characteristics may influence vaccine choices. However, these individual characteristics represent
only a starting point in delivering tailored messages that should come from trusted sources to address vaccination barriers.

Acknowledgments
Thank you to the respondents for their time in completing our survey and to Lee Ann Waldron for her assistance with survey promotion. We appreciate the support of our advisory board members and our colleagues who helped in survey refinement.

This work was funded by a Merck Investigators Studies Program Grant: VAccination Challenges through Community-Identified NEeds (VACCINE). The funder was not directly involved in any of the study work.

Conflicts of Interest
KC works as a consultant for Seqirus, Inc and Idaho Immunization Coalition. All other authors declare that they have no conflicts of interest related to the manuscript.

Multimedia Appendix 1
Study survey. [DOCX File, 42 KB-Multimedia Appendix 1]

Multimedia Appendix 2
Age distribution. [PDF File (Adobe PDF File), 40 KB-Multimedia Appendix 2]

References
1. Andre F, Booy R, Bock H, Clemens J, Datta S, John T, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008 Feb 1;86(2):140-146 [FREE Full text] [doi: 10.2471/blt.07.040089] [Medline: 18297169]
2. Immunization. UNICEF. URL: https://www.unicef.org/immunization [accessed 2022-09-09]
3. Myths and Facts about COVID-19 Vaccines. Centers for Disease Control and Prevention. 2022 Jul 20. URL: https://tinyurl.com/bdcp4web [accessed 2022-09-09]
4. Eibensteiner F, Ritschl V, Nawaz FA, Fazel SS, Tsagkaris C, Kulnik ST, et al. People's willingness to vaccinate against COVID-19 despite their safety concerns: Twitter poll analysis. J Med Internet Res 2021 Apr 29;23(4):e28973 [FREE Full text] [doi: 10.2196/28973] [Medline: 33872185]
5. Siddiqui M, Salmon DA, Omer SB. Epidemiology of vaccine hesitancy in the United States. Hum Vaccin Immunother 2013 Dec 01;9(12):2643-2648 [FREE Full text] [doi: 10.4161/hv.27243] [Medline: 24247148]
6. Building Confidence in COVID-19 Vaccines. Centers for Disease Control and Prevention. URL: https://www.cdc.gov/vaccines/covid-19/vaccinate-with-confidence.html [accessed 2022-09-09]
7. World Health Organization. Report of the Sage Working Group on Vaccine Hesitancy. MedBox. 2014. URL: https://www.medbox.org/document/report-of-the-sage-working-group-on-vaccine-hesitancy#GQ [accessed 2022-09-09]
8. Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: understanding better to address better. Isr J Health Policy Res 2016 Feb 1;5(1):2 [FREE Full text] [doi: 10.1186/s13584-016-0062-y] [Medline: 26839681]
9. Lewis JR. What is driving the decline in people’s willingness to take the COVID-19 vaccine in the United States? JAMA Health Forum 2020 Nov 18;1(11):e201393. [doi: 10.1001/jamahealthforum.2020.1393]
10. Herd immunity and COVID-19: What you need to know. Mayo Clinic. URL: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808 [accessed 2022-09-09]
11. Bolotin S, Wilson S, Murti M. Achieving and sustaining herd immunity to SARS-CoV-2. CMAJ 2021 Jul 19;193(28):E1089-E1089 [FREE Full text] [doi: 10.1503/cmaj.210892] [Medline: 34281966]
12. COVID Data Tracker. Centers for Disease Control and Prevention. URL: https://covid.cdc.gov/covid-data-tracker/#datatracker-home [accessed 2022-09-09]
13. Karafillakis E, Larson H. The paradox of vaccine hesitancy among healthcare professionals. Clin Microbiol Infect 2018 Aug;24(8):799-800 [FREE Full text] [doi: 10.1016/j.cmi.2018.04.001] [Medline: 29649595]
14. Lyu H, Wang J, Wu W, Duong V, Zhang X, Dye TD, et al. Social media study of public opinions on potential COVID-19 vaccines: informing dissent, disparities, and dissemination. Intell Med 2022 Feb;2(1):1-12 [FREE Full text] [doi: 10.1016/imed.2021.08.001] [Medline: 34457371]
15. Savoia E, Pilth-Loeb R, Goldberg B, Miller-Idriss C, Hughes B, Montrond A, et al. Predictors of COVID-19 vaccine hesitancy: socio-demographics, co-morbidity, and past experience of racial discrimination. Vaccines (Basel) 2021 Jul 09;9(7):767 [FREE Full text] [doi: 10.3390/vaccines9070767] [Medline: 34358184]
16. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine 2020 Sep 29;38(42):6500-6507 [FREE Full text] [doi: 10.1016/j.vaccine.2020.08.043] [Medline: 32863069]

17. Lin Y, Hu Z, Zhao Q, Alias H, Danace M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis 2020 Dec 17;14(12):e0008961 [FREE Full text] [doi: 10.1371/journal.pntd.0008961] [Medline: 33332359]

18. Zhou Y, Zhang J, Wu W, Liang M, Wu Q. Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China. BMC Public Health 2021 Jun 09;21(1):1103 [FREE Full text] [doi: 10.1186/s12889-021-11174-0] [Medline: 34107930]

19. Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines (Basel) 2021 Mar 03;9(3):210 [FREE Full text] [doi: 10.3390/vaccines9030210] [Medline: 33802285]

20. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine 2020 Nov 17;38(49):7789-7798 [FREE Full text] [doi: 10.1016/j.vaccine.2020.10.027] [Medline: 33109389]

21. Kumari A, Ranjan P, Chopra S, Kaur D, Kaur T, Upadhyay AD, et al. Knowledge, barriers and facilitators regarding COVID-19 vaccine and vaccination programme among the general population: A cross-sectional survey from one thousand two hundred and forty-nine participants. Diabetes Metab Syndr 2021 May;15(5):987-992 [FREE Full text] [doi: 10.1016/j.dsx.2021.04.015] [Medline: 33984818]

22. Larson H, Schulz W, Tucker J, Smith D. Measuring vaccine confidence: introducing a global vaccine confidence index. PLoS Curr 2015 Feb 25;7:1 [FREE Full text] [doi: 10.1371/currents.outbreaks.ce06177bc97332602a8e3fe7d7f7cc4] [Medline: 25789200]

23. Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, SAGE Working Group on Vaccine Hesitancy. Measuring vaccine hesitancy: The development of a survey tool. Vaccine 2015 Aug 14;33(34):4165-4175 [FREE Full text] [doi: 10.1016/j.vaccine.2015.04.037] [Medline: 25896384]

24. KFF COVID-19 Vaccine Monitor: July 2021. Kaiser Family Foundation. 2021 Aug 04. URL: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-july-2021/ [accessed 2022-09-09]

25. Mentzer R. GOP Men Are Most Likely To Say They’ll Refuse COVID-19 Vaccine. Wisconsin Public Radio. 2021 Mar 17. URL: https://www.wpr.org/gop-men-are-most-likely-say-theyll-refuse-covid-19-vaccine [accessed 2022-09-09]

26. Party affiliation among adults in Alaska. Pew Research Center. URL: https://www.pewforum.org/religious-landscape-study/state/alaska/party-affiliation/ [accessed 2022-09-09]

27. Party affiliation among adults in Idaho. Pew Research Center. URL: https://www.pewforum.org/religious-landscape-study/state/idaho/party-affiliation/ [accessed 2022-09-09]

28. Okuhara T, Ishikawa H, Ueno H, Okada H, Kato M, Kiuichi T. Readability assessment of vaccine information: A systematic review for addressing vaccine hesitancy. Patient Educ Couns 2022 Feb;105(2):331-338. [doi: 10.1016/j.pec.2021.05.039] [Medline: 34090717]

29. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination. Centers for Disease Control and Prevention. 2022 Jul 14. URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html [accessed 2022-09-09]

30. Bara N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021 Sep 16;385(12):1078-1090. [doi: 10.1056/nejmoa2110475]

31. Vaccine Safety. Centers for Disease Control and Prevention. URL: https://www.cdc.gov/vaccinesafety/index.html [accessed 2022-09-09]

32. New Poll Reveals Most Effective Language to Improve COVID-19 Vaccine Acceptance, de Beaumont. 2020 Dec. URL: https://debeaumont.org/changing-the-covid-conversation/vaccineacceptance/ [accessed 2022-09-09]

33. Lewis-Parmar H, McCann R. Achieving national influenza vaccine targets—an investigation of the factors affecting influenza vaccine uptake in older people and people with diabetes. Commun Dis Public Health 2002 Jun;5(2):119-126. [Medline: 12166297]

34. Lin CI, Nowalk MP, Zimmerman RK, Ko F, Zoffel L, Hoberman A, et al. Beliefs and attitudes about influenza immunization among parents of children with chronic medical conditions over a two-year period. J Urban Health 2006 Sep 13;83(5):874-883 [FREE Full text] [doi: 10.1007/s11524-006-9084-z] [Medline: 16770701]

35. Kahn KE, Santibanez TA, Zhai Y, Bridges CB. Association between provider recommendation and influenza vaccination status among children. Vaccine 2018 Jun 07;36(24):3486-3497 [FREE Full text] [doi: 10.1016/j.vaccine.2018.04.077] [Medline: 29764679]

36. Levy A. The social network for doctors is full of vaccine disinformation. CNBC. 2021 Aug 06. URL: https://www.cnbc.com/2021/08/06/doximity-social-network-for-doctors-full-of-antivax-disinformation.html [accessed 2022-09-09]

37. Brumfiel G. This Doctor Spread False Information About COVID. She Still Kept Her Medical License. NPR. 2021 Sep 14. URL: https://www.npr.org/sections/health-shots/2021/09/14/1035915598/doctors-covid-misinformation-medical-license [accessed 2022-09-09]
38. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat Hum Behav 2021 Mar 05;5(3):337-348. [doi: 10.1038/s41562-021-01056-1] [Medline: 33547453]

39. Health Misinformation. Office of the U.S. Surgeon General. URL: https://www.hhs.gov/surgeongeneral/reports-and-publications/health-misinformation/index.html [accessed 2022-09-09]

40. FDA Approves First COVID-19 Vaccine. Food & Drug Administration. 2021 Aug 23. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine [accessed 2022-09-09]

41. What Is Vaccine Confidence? Centers for Disease Control and Prevention. URL: https://www.cdc.gov/vaccines/covid-19/vaccinate-with-confidence/building-trust.html [accessed 2022-09-07]

Abbreviations

FDA: Food and Drug Administration
SAGE: Strategic Advisory Group on Experts
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
WHO: World Health Organization